Mesa Laboratories MLAB Biopharmaceutical Development — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's biopharmaceutical development — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's biopharmaceutical development — gross profit?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — gross profit of $5.2M in Q1 2026.
- How has Mesa Laboratories's biopharmaceutical development — gross profit changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — gross profit decreased by 28.3% year-over-year, from $7.25M to $5.2M.
- What is the long-term trend for Mesa Laboratories's biopharmaceutical development — gross profit?
- Over 4 years (2022 to 2026), Mesa Laboratories's biopharmaceutical development — gross profit has grown at a -0.0% compound annual growth rate (CAGR), from $28.61M to $28.55M.
- What does biopharmaceutical development — gross profit mean?
- Calculated as the total revenue of the Biopharmaceutical Development segment minus the total cost of revenue. This metric measures the profitability of the segment's core production and service delivery before accounting for operating expenses like R&D, sales, or administration. It indicates the segment's ability to manage production costs and maintain pricing power.